Lentiviral Vector bLCR-EFS Promoter for Lysosomal Storage Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for lysosomal storage diseases (LSDs) face challenges in achieving sustained and widespread expression of therapeutic enzymes, leading to incomplete correction of organ pathology and safety concerns due to high vector copy numbers and immune responses.
Innovation Solution
A lentiviral gene therapy vector utilizing the β-globin locus control region (bLCR) linked to the elongation factor 1α (EFS) promoter for high-level expression in hematopoietic stem cells, achieving systemic delivery and significant upregulation in erythroid cells, thereby enhancing enzyme activity in multiple tissues with lower vector copy numbers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy vectors are used to deliver therapeutic genes, then enzyme production is achieved in some cells, but the levels and duration of gene expression are insufficient to correct systemic and CNS pathology
Solution Approach 1:
The promoter is segmented into two functional parts: the EFS promoter providing basal expression and the bLCR elements (HS2, HS3, HS4) providing erythroid-specific upregulation. This segmentation allows the vector to achieve both moderate constitutive expression across cell types and high-level expression in erythroid cells, resolving the contradiction between expression level and breadth of correction.
Solution Approach 2:
The bLCR elements provide localized enhancement of promoter activity specifically in erythroid cells while maintaining basal activity in other cell types through the EFS promoter. This local quality approach ensures that erythroid cells receive high-level enzyme production while other cells maintain sufficient expression levels, thereby expanding the breadth of correction without sacrificing expression intensity.
2Reliability
If high vector copy numbers are used to achieve sufficient enzyme production, then enzyme levels improve, but safety concerns arise due to immune responses and genomic disruption
Solution Approach 1:
The invention changes the regulatory parameters of gene expression by introducing bLCR elements that increase promoter activity specifically in erythroid cells. This parameter change allows achieving high enzyme production levels with lower vector copy numbers, thereby reducing the risks of immune response and genomic disruption associated with high vector loads.
3Reliability
If existing treatment options like bone marrow transplantation are used, then some enzyme correction is achieved, but effectiveness is limited by donor availability and adverse immune responses
Solution Approach 1:
The autologous HSC gene therapy approach allows patients to receive their own corrected cells, eliminating the need for donor matching and reducing immune rejection risks. The bLCR-EFS vector system enables these self-service transplanted cells to produce high levels of enzyme specifically in erythroid cells, achieving effective correction without the limitations of donor availability and immune compatibility.
Data Source
AI summary
The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient.